Publicaciones (59) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021–2030): a societal perspective

    Health Economics Review, Vol. 14, Núm. 1

  2. Conjunctival ultraviolet autofluorescence as a biomarker of outdoor exposure in myopia: a systematic review and meta-analysis

    Scientific Reports, Vol. 14, Núm. 1

  3. Could Children’s Myopization Have Been Avoided during the Pandemic Confinement? The Conjunctival Ultraviolet Autofluorescence (CUVAF) Biomarker as an Answer

    Biomedicines, Vol. 12, Núm. 2

  4. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

    Ophthalmology, Vol. 131, Núm. 6, pp. 708-723

  5. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

  6. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

    Ophthalmic research, Vol. 67, Núm. 1, pp. 311-321

  7. Suitability of machine learning for atrophy and fibrosis development in neovascular age-related macular degeneration

    Acta Ophthalmologica, Vol. 102, Núm. 5, pp. e831-e841

  8. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

  9. The Scavenging Activity of Coenzyme Q10 Plus a Nutritional Complex on Human Retinal Pigment Epithelial Cells

    International Journal of Molecular Sciences, Vol. 25, Núm. 15

  10. Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

    Ophthalmology and Therapy

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Análisis coste-utilidad del modelo de unidad de terapia intravítrea (UTI) frente a la administración tradicional de terapia intravítrea

    Archivos de la Sociedad Española de Oftalmologia, Vol. 98, Núm. 11, pp. 619-626

  3. Blue Light Exposure: Ocular Hazards and Prevention—A Narrative Review

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 755-788

  4. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

  5. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1449-1458

  6. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

    Japanese Journal of Ophthalmology, Vol. 67, Núm. 3, pp. 264-279

  7. Matrix Metalloproteinase 13 Is Associated with Age-Related Choroidal Neovascularization

    Antioxidants, Vol. 12, Núm. 4

  8. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

    Biological Psychiatry, Vol. 93, Núm. 9, pp. 770-779

2022

  1. A Cross-Sectional Observational Study of the Relationship between Outdoor Exposure and Myopia in University Students, Measured by Conjunctival Ultraviolet Autofluorescence (CUVAF)

    Journal of Clinical Medicine, Vol. 11, Núm. 15

  2. A Screening Tool for Self-Evaluation of Risk for Age-Related Macular Degeneration: Validation in a Spanish Population

    Translational Vision Science and Technology, Vol. 11, Núm. 6